Prestige Consumer Healthcare In

Valuation Analysis

About the Company

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the De

Prestige Consumer Healthcare In Stock at a Glance

Prestige Consumer Healthcare In (PBH) is currently trading at $47.82 with a market capitalization of $2.3B. The trailing P/E ratio stands at 12.23x, with a forward P/E of 9.53x. The 52-week range spans from $42.62 to $85.29; the current price is 43.9% below the yearly high. Year-over-year revenue growth stands at -5.0%. The net profit margin stands at 17.48%.

💰 Dividend

Prestige Consumer Healthcare In currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

5 analysts rate Prestige Consumer Healthcare In (PBH) on consensus: Buy. The average price target is $66.80, implying +39.69% from the current price. Analyst price targets range from $50.00 to $75.00.

Prestige Consumer Healthcare In: The Investment Case in Detail

Prestige Consumer Healthcare In (PBH) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

The combination of a 55.65% gross margin and 26.81% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Free cash flow is positive and net margins stand at 17.48%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 39.69% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Revenue is contracting at -5% year-over-year — until that trend reverses, valuation is exposed to further downgrades.

Valuation in Context

The PEG ratio at 1.45 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9.53x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The forward P/E of 9.53x is meaningfully below the trailing 12.23x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 39.69% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Risk Profile

The data points to relatively defensive market behavior, elevated short interest (7.38%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Prestige Consumer Healthcare In?

Compare top-rated brokers — low fees, trusted providers, fully regulated.